June 10, 2024
LISBON — The diabetes and weight-loss drug semaglutide improves heart failure–related symptoms and physical limitations regardless of diuretic use in patients with obesity-related heart failure and […]
June 10, 2024
MILAN — Tirzepatide, a glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) receptor agonist, was more effective than placebo was in the resolution of metabolic […]
June 10, 2024
An 11-member advisory panel to the US Food and Drug Administration (FDA) has unanimously concluded that the investigational anti-amyloid donanemab is effective for the treatment of […]
June 10, 2024
LISBON — Patients with decompensated heart failure who have bendopnea on discharge from hospital appear to be at significantly increased risk for all-cause mortality within 2 […]
June 10, 2024
Everyone deserves confidence in their next dose of medicine. A quality medicine is safe, effective, and available for the people who need it. The Office of […]
June 10, 2024
The European Alliance of Associations for Rheumatology (EULAR) 2024 European Congress of Rheumatology Annual Meeting is about to take place in Vienna, Austria. From June 12-15, […]
June 10, 2024
Please see the list below for available calendar year reports on New Drug Application (NDA) and Biologic License Application (BLA) approvals. Reports Resources Content current as of: 09/29/2017 Regulated […]
June 10, 2024
Drugs@FDAIncludes information about drugs approved for human use in the United States: Drug information, Regulatory history, Most recent FDA-approved Prescribing Information and patient labeling, and Reviews […]
June 10, 2024
HOW TO USE THIS SNAPSHOTThe information provided in Snapshots highlights who participated in the key clinical trials that supported the original FDA approval of this drug, […]